Published in Diabetes Care on April 14, 2009
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 1.95
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes (2011) 1.42
Management of diabetes mellitus in infants. Nat Rev Endocrinol (2011) 1.40
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes (2009) 1.39
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab (2013) 1.25
Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease. Diabetes Care (2015) 1.25
Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care (2009) 1.20
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest (2015) 1.19
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes (2012) 1.07
Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol (2013) 1.06
Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care (2011) 0.97
The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes. Cell Calcium (2011) 0.95
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol (2011) 0.92
Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes (2012) 0.89
Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr (2010) 0.88
The role of TNF-α in mice with type 1- and 2- diabetes. PLoS One (2012) 0.87
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol (2015) 0.85
Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol (2013) 0.84
Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto's thyroiditis successfully treated with etanercept. Ital J Pediatr (2013) 0.83
Prevention of type 1 diabetes. Endocrinol Metab Clin North Am (2009) 0.82
Transcription of the gene encoding TNF-α is increased by IL-1β in rat and human islets and β-cell lines. Mol Immunol (2014) 0.81
Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev Diabet Stud (2012) 0.81
Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80
Innate inflammation in type 1 diabetes. Transl Res (2015) 0.80
Treatment of LADA with etanercept. Diabetes Care (2012) 0.78
Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study: response to Mastrandrea et al. Diabetes Care (2009) 0.78
Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol (2014) 0.78
Targeted immune interventions for type 1 diabetes: not as easy as it looks! Curr Opin Endocrinol Diabetes Obes (2014) 0.77
Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse. Hum Vaccin Immunother (2013) 0.77
Enhanced apoptosis of monocytes from complication-free juvenile-onset diabetes mellitus type 1 may be ameliorated by TNF-α inhibitors. Mediators Inflamm (2014) 0.76
Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes Care (2013) 0.76
Immunotherapy in autoimmune type 1 diabetes. Rev Diabet Stud (2012) 0.76
Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series. J Med Case Rep (2012) 0.75
The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice. J Diabetes Res (2016) 0.75
Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes. Pharmacogenomics J (2016) 0.75
Strategies for clinical trials in type 1 diabetes. J Autoimmun (2016) 0.75
Targeting Innate Immunity for Type 1 Diabetes Prevention. Curr Diab Rep (2017) 0.75
Dominant TNFα and impaired IL-2 cytokine profiles of CD4(+) T cells from children with type-1 diabetes. Immunol Cell Biol (2017) 0.75
A guiding map for inflammation. Nat Immunol (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Adjustment to diabetes mellitus in preschoolers and their mothers. Diabetes Care (1989) 1.89
Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes (1988) 1.85
IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol (1988) 1.83
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol (1987) 1.74
Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A (1990) 1.28
Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest (2004) 1.26
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) (2007) 1.11
Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med (2000) 1.11
Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine (1993) 1.09
Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol (1991) 1.08
Effects of cytokines on rat pancreatic islet cell monolayer cultures: distinction between functional and cytotoxic effects on islet beta-cells. Reg Immunol (1990) 1.01
Stress in parents of children with diabetes mellitus. Diabetes Care (1989) 1.00
Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinol (Copenh) (1988) 0.99
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) (2007) 0.94
A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci U S A (2000) 0.91
Cytokines and diabetes: the final step? Involvement of TNF-alpha in both type I and II diabetes mellitus. Horm Metab Res (1994) 0.90
Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. Eur J Endocrinol (2007) 0.87
Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods (2012) 2.01
Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2002) 1.83
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
Q-learning: a data analysis method for constructing adaptive interventions. Psychol Methods (2012) 1.51
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma (2006) 1.46
A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care (2009) 1.45
Young adult educational and vocational outcomes of children diagnosed with ADHD. J Abnorm Child Psychol (2013) 1.43
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
The academic experience of male high school students with ADHD. J Abnorm Child Psychol (2011) 1.37
Two-sample density-based empirical likelihood tests for incomplete data in application to a pneumonia study. Biom J (2011) 1.34
Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 1.32
Late adolescent and young adult outcomes of girls diagnosed with ADHD in childhood: an exploratory investigation. J Atten Disord (2010) 1.19
Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.18
Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care (2008) 1.11
Two-sample nonparametric likelihood inference based on incomplete data with an application to a pneumonia study. Biom J (2010) 1.11
Efficacy of family-based weight control program for preschool children in primary care. Pediatrics (2012) 1.08
Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology (2007) 1.06
DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res (2006) 1.04
Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol (2006) 1.02
Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care (2003) 0.99
Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology (2004) 0.96
Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer (2006) 0.95
Testosterone concentrations in young pubertal and post-pubertal obese males. Clin Endocrinol (Oxf) (2013) 0.94
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer (2005) 0.93
Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res (2004) 0.92
Duplication of dosage sensitive sex reversal area in a 46, XY patient with normal sex determining region of Y causing complete sex reversal. J Pediatr Endocrinol Metab (2013) 0.92
A waitlist-controlled trial of behavioral parent training for fathers of children with ADHD. J Clin Child Adolesc Psychol (2012) 0.90
CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg (2007) 0.87
Screening obese students for acanthosis nigricans and other diabetes risk factors in the urban school-based health center. Clin Pediatr (Phila) (2011) 0.87
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma (2009) 0.87
Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood. Atherosclerosis (2013) 0.86
Development and validation of the WEll-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE). Health Qual Life Outcomes (2008) 0.84
Nonclinical factors associated with primary care physicians' ordering patterns of magnetic resonance imaging/computed tomography for headache. Acad Radiol (2004) 0.83
Diminished insulin resistance with weight loss in severely overweight youth. Metab Syndr Relat Disord (2004) 0.82
Women with Childhood ADHD: Comparisons by Diagnostic Group and Gender. J Psychopathol Behav Assess (2011) 0.82
High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med (2006) 0.82
Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev (2006) 0.81
Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study. Prostate (2005) 0.80
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology (2007) 0.80
Analysis of cigarette purchase task instrument data with a left-censored mixed effects model. Exp Clin Psychopharmacol (2013) 0.79
Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol (2007) 0.78
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anticancer Drugs (2008) 0.78
Evaluations and comparisons of treatment effects based on best combinations of biomarkers with applications to biomedical studies. J Comput Biol (2014) 0.77
Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer (2007) 0.76
Computing Critical Values of Exact Tests by Incorporating Monte Carlo Simulations Combined with Statistical Tables. Scand Stat Theory Appl (2014) 0.75
Key diagnostic finding in a condition with variable clinical presentations. Case Rep Pediatr (2013) 0.75
Does the dopamine transporter protein allele predict growth hormone testing results or response to growth hormone therapy? Endocrine (2010) 0.75
Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial. J Pediatr Endocrinol Metab (2008) 0.75
Weight trajectory of youth with new-onset type 1 diabetes comparing standard and enhanced dietary education. Endocrine (2014) 0.75
High-Risk Factors in Symptomatic Patients Undergoing Carotid Artery Stenting With Distal Protection: Buffalo Risk Assessment Scale (BRASS). Neurosurgery (2015) 0.75
Detecting overweight children in primary care: do national data reflect the typical urban practice? J Fam Pract (2006) 0.75
In Reply: High-Risk Factors in Symptomatic Patients Undergoing Carotid Artery Stenting With Distal Protection: Buffalo Risk Assessment Scale (BRASS). Neurosurgery (2016) 0.75
Linkage to primary medical care following inpatient detoxification. Am J Addict (2007) 0.75
Correspondence re: Chokkalingam A. et al., Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomark. Prev., 10: 421-427, 2001. Cancer Epidemiol Biomarkers Prev (2002) 0.75